Results 91 to 100 of about 69,008 (285)

Improving HER2 Diagnostics with Digital Real‐Time PCR for Ultrafast, Precise Prediction of Anti‐HER2 Therapy Response in Patients with Breast Cancer

Small Methods, EarlyView.
This study presents a novel, clinically feasible HER2 testing method using a fully automated digital real‐time PCR platform. It enables real‐time absolute quantification of ERBB2 copy number alterations for rapid, simple, and accurate assessment of HEgR2 status, thereby overcoming the limitations of conventional testing and improving prediction of anti‐
Hee‐Joo Choi, Soo Young Park, Minsik Song, Jinhyuk Chang, YoonSik Kim, Hosub Park, Chihwan David Cha, Sohyeon Yang, Nam Hun Heo, Min Ji Song, Da Sol Kim, Hayeon Kim, Minuk Kim, Jae Eun Park, Yesung Lee, EunChae Ji, Heekyoung Chung, Ilecheon Jeong, Mineui Hong, Jin‐Wu Nam, Mee‐Hye Oh, Ji‐Hye Lee, Jinwoo Seol, Hee‐Young Won, Hyun‐Woo Song, Jaewon Eom, Do Young Lee, Han Suk Ryu, Si‐Hyong Jang, Jeong‐Yeon Lee   +29 more
wiley   +1 more source

<p>Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy</p>

, 2020
Fadilah Sfouq Aleanizy, Fulwah Yahya Alqahtani, Sara Setó, Nora Khalil, Lama Aleshaiwi, Manar Alghamdi, Bushra T. AlQuadeib, Hamad M. Alkahtani, Amal Aldarwesh, Qamraa H. Alqahtani, Hosam Gharib Abdelhady, Ibrahim A. Alsarra   +11 more
openalex   +2 more sources

Data from Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization

, 2023
Bohua Li, Yanchun Meng, Lei Zheng, Xunmin Zhang, Qing Tong, Wenlong Tan, Shi Hu, Hui Li, Yang Chen, Jinjing Song, Ge Zhang, Lei Zhao, Dapeng Zhang, Sheng Hou, Weizhu Qian, Yajun Guo   +15 more
openalex   +1 more source

Recent Advances in Bioconjugation of Aromatic Amino Acid Residues by a Reactivity‐Guided Approach

The Chemical Record, EarlyView.
This review highlights recent advances in the bioconjugation of aromatic amino acids residues, focusing on strategies that leverage their inherent chemical reactivity to enable precise and versatile modifications of biomacromolecules, illustrating relevant applications.
Bruno M. da S. Santos, Lívia C. R. M. da Frota, Thais G. Silva, Fernanda G. Finelli   +3 more
wiley   +1 more source

Supplementary Materials and Methods, Supplementary Schemes 1 through 3, Supplementary Figures 1 through 6 and Supplementary Table 1 from A Novel Platinum(II)–Based Bifunctional ADC Linker Benchmarked Using ⁸⁹Zr-Desferal and Auristatin F–Conjugated Trastuzumab

, 2023
Niels J. Sijbrandi, Eugen Merkul, Joey A. Muns, Dennis C. J. Waalboer, Kevin Adamzek, Marije Bolijn, Verónica Montserrat, Govert W. Somsen, Rob Haselberg, Paul J.G.M. Steverink, Hendrik‐Jan Houthoff, Guus A.M.S. van Dongen   +11 more
openalex   +1 more source

Mass spectrometry‐based mitochondrial proteomics for cancer biomarker discovery

VIEW, EarlyView.
Figure.1 Schematic diagram of MS‐based mitochondrial proteomics for cancer biomarker discovery. The workflow highlights the integration of advanced technological platforms in mitochondrial proteomics and their application in cancer biomarker discovery.
Zheng Cao, ZiKun Song, Weijie Zhou, Xiaohui Liu, Yanling Liu, Peng R. Chen, Kun Qian   +6 more
wiley   +1 more source

Supplementary Figures 1-3 from β₁-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer

, 2023
David Lesniak, Yaoxian Xu, Jean Deschênes, Raymond Lai, John Thoms, David J. Murray, Sunita Gosh, John R. Mackey, Siham Sabri, Bassam Abdulkarim   +9 more
openalex   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Correlation between resistance to trastuzumab and miR-141 relative expression in the BT-474 human breast cancer cell line

مجله دانشگاه علوم پزشکی بیرجند, 2017
Background and Aim: Resistance to trastuzumab has been a critical barrier to targeted therapy of HER 2-positive (Human Epidermal Growth Factor Receptor 2) breast cancers.
Zohreh Rezaei, Dor Mohammad Kordi-Tamandani, Ahmadreza Sebzari, Kazem Dastjerdi   +3 more
doaj  

Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

, 2023
Maurizio Scaltriti, Paolo Nucíforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor‐Tarh, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluís Parra, Ludmila Prudkin, José Jiménez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquı́n Arribas, Javier Cortés, Evandro de Azambuja, Martine Piccart, José Baselga   +21 more
openalex   +1 more source